Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis-Reference-Cited by-同舟云学术

Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Published:2021-03 Issue:3 Volume:9 Page:1389-1392.e2
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Achten Roselie,Bakker Daphne,Ariens Lieneke,Lans Amanda,Thijs Judith,van der Schaft Jorien,de Boer Joke,Balak Deepak,de Graaf Marlies,van Luijk Chantal,de Bruin-Weller Marjolein

Funder

Sanofi Genzyme

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference9 articles.

1. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

2. Conjunctivitis in dupilumab clinical trials;Akinlade;Br J Dermatol,2019

3. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry;Ariens;Allergy,2020

4. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis;Bakker;Br J Dermatol,2019

5. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2017

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular surface disease in moderate‐to‐severe atopic dermatitis patients and the effect of biological therapy;Clinical & Experimental Allergy;2024-02-08

2. Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors;American Journal of Clinical Dermatology;2024-01-12

3. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs;Allergy;2024-01-08

4. Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry;Journal of the European Academy of Dermatology and Venereology;2023-11-29

5. Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps;Journal of Dermatological Treatment;2023-09-04